What Diseases Are Associated With a Positive Anti-CCP?

A positive anti-CCP (anti-cyclic citrullinated peptide) test is most strongly linked to rheumatoid arthritis, where it serves as one of the most specific blood markers available. A large meta-analysis found anti-CCP antibodies have about 95% specificity for RA, meaning a positive result rarely points to something else.¹ But “rarely” is not “never,” and a positive anti-CCP does turn up in a handful of other conditions, from lupus to lung disease to certain infections. Understanding this broader picture matters for anyone trying to make sense of an unexpected lab result.

The Strongest Link Is Rheumatoid Arthritis

Anti-CCP antibodies target proteins that have undergone a chemical change called citrullination, and the immune system’s attack on these altered proteins is a central feature of RA. In the meta-analysis mentioned above, anti-CCP had a pooled sensitivity of about 67%, meaning it catches roughly two-thirds of RA cases, while its specificity of 95% makes false positives uncommon.¹ Compare that with rheumatoid factor (RF), the older and more familiar test, which had similar sensitivity but only about 85% specificity. In practical terms, anti-CCP is much better at ruling RA in when positive, though a negative result does not rule it out.

What makes anti-CCP especially useful is that it can show up years before any joint symptoms begin. A study tracking blood donors who later developed RA found that about half were positive for RF and/or anti-CCP on at least one blood sample drawn a median of 4.5 years before symptoms appeared.² This pre-clinical window is one reason rheumatologists value the test so highly: it can flag people at risk before damage starts.

How Anti-CCP Predicts Worse Joint Damage

Beyond diagnosing RA, the test carries prognostic weight. People who are anti-CCP positive at diagnosis tend to develop more severe erosive disease over time. One study found that anti-CCP positivity was significantly correlated with more severe joint damage at the time of diagnosis, independent of RF status.³ Longer follow-up data confirm the pattern: a study tracking patients over a decade found that baseline anti-CCP and C-reactive protein predicted radiographic outcome at both five and ten years.⁴

A separate analysis showed that among several potential predictors of joint erosion, anti-CCP had the highest odds ratio for radiographic damage and progression, ranking above RF, ESR, age, smoking status, and sex.⁵ For clinicians, this often tips the balance toward starting more aggressive treatment earlier in anti-CCP-positive patients.

Systemic Lupus Erythematosus and Rhupus

Lupus (SLE) is one of the more common non-RA conditions where anti-CCP shows up. A Brazilian cross-sectional study found that about 14% of SLE patients tested positive for anti-CCP, a rate significantly higher than healthy controls but much lower than in RA.⁶ Interestingly, the anti-CCP-positive lupus patients in that study did not have a distinct joint profile compared to those who were negative. They did, however, have a higher prevalence of other autoantibodies, specifically anti-Ro and anti-La.

A positive anti-CCP in someone with lupus also raises the question of “rhupus,” an overlap syndrome where features of both RA and SLE coexist. A study of 56 rhupus patients found that RF and anti-CCP were significantly more common in this group than in standard SLE. Rhupus patients tend to develop severe, erosive, and deforming joint disease while having relatively mild lupus activity and less organ involvement.⁷ So when anti-CCP turns up in a lupus patient, it can be a signal that RA-like joint disease may be in the picture.

Sjögren’s Syndrome

In primary Sjögren’s syndrome, anti-CCP shows up in a meaningful minority of patients, and its presence has a specific clinical implication: joint inflammation. One study of 141 patients found about 10% had moderate to high anti-CCP levels, and multivariate analysis showed a strong association between anti-CCP and non-erosive synovitis, with the odds of synovitis roughly seven times higher in anti-CCP-positive patients.⁸ A separate study in 95 patients found a higher prevalence of about 22%, and again, anti-CCP-positive patients had non-erosive arthritis far more frequently than those who were negative (76% versus 22%).⁹

The pattern here is consistent: anti-CCP in Sjögren’s doesn’t seem to predict the extra-glandular complications people worry about most, like lung or kidney involvement. Instead, it flags a subset of patients who develop joint inflammation, though unlike RA, the arthritis in Sjögren’s is typically non-erosive, meaning it doesn’t cause the same kind of permanent bone damage.

Psoriatic Arthritis

Psoriatic arthritis and RA can look alike in the exam room, especially when PsA follows a polyarticular pattern, and anti-CCP testing occasionally complicates the picture. The antibody is found in roughly 5-12% of PsA patients depending on the study. One analysis found anti-CCP in about 6% of PsA patients, compared to 97% of seropositive RA patients and 0% of controls.¹⁰ Another study found 7% positivity in PsA versus 74% in early RA, and logistic regression confirmed that anti-CCP (along with RF) could significantly distinguish between the two diseases.¹¹

The PsA patients who do test anti-CCP positive tend to look more like RA patients clinically. One cross-sectional study found they had polyarticular disease more frequently and were more likely to be on biologic therapy. The researchers even identified an anti-CCP titer threshold above which a person thought to have PsA probably has RA and psoriasis co-occurring rather than PsA alone.¹² This distinction matters because treatment strategies differ.

Systemic Sclerosis

Systemic sclerosis (scleroderma) itself is not commonly associated with anti-CCP. In one study, only about 3% of SSc patients tested positive.¹³ But when anti-CCP does appear in someone with scleroderma, it strongly suggests an overlap syndrome with RA. In the same study, 86% of patients who had both scleroderma and RA (SSc-RA overlap) tested positive, and their anti-CCP levels were significantly higher than in SSc patients without RA features. A separate analysis found anti-CCP positivity only in patients with confirmed SSc-RA overlap, not in those with scleroderma alone.¹⁴

An important clinical detail: almost all SSc-RA overlap patients with elevated anti-CCP had both joint pain and interstitial lung disease, suggesting the antibody may help identify a subset of scleroderma patients at particular risk for both erosive arthritis and pulmonary complications.¹³

Interstitial Lung Disease Without Clear RA

Anti-CCP sometimes surfaces in patients who have interstitial lung disease (ILD) but no obvious joint symptoms. This creates a diagnostic gray zone. The concept of “interstitial pneumonia with autoimmune features” (IPAF) was developed to describe patients with ILD and some autoimmune markers, including anti-CCP, who don’t fully meet criteria for any specific connective tissue disease. IPAF criteria are met in up to a quarter of ILD patients, and that group includes people with anti-CCP but no RA joint involvement.¹⁵

When researchers compared patients with connective-tissue-disease-related ILD against those with IPAF, anti-CCP positivity was one of several factors that distinguished the connective tissue disease group, meaning it may help flag which ILD patients have an underlying autoimmune condition driving their lung problems.¹⁶ For pulmonologists, an anti-CCP result can be a useful piece of a larger puzzle when a patient shows up with unexplained lung scarring.

Palindromic Rheumatism

Palindromic rheumatism is a condition marked by recurrent, short-lived episodes of joint pain and swelling that resolve completely between attacks. It’s often considered a possible precursor to full-blown RA. A positive anti-CCP in someone with palindromic rheumatism significantly increases the chance of progressing to RA. One follow-up study found that hand joint involvement and positive anti-CCP at disease onset were the only independent predictors of progression to RA within a year.¹⁷ This makes anti-CCP testing particularly informative in this group: a negative result is somewhat reassuring, while a positive result justifies closer monitoring or even early treatment to prevent joint damage.

Juvenile Idiopathic Arthritis in Children

Anti-CCP is much less commonly positive in children with juvenile idiopathic arthritis (JIA) than in adults with RA. One study of 50 JIA patients found only 8% were anti-CCP positive, and all of them had polyarticular-onset disease.¹⁸ A larger multicenter trial found a higher rate of about 24%, again concentrated in the polyarticular subgroup. In that study, anti-CCP-positive children had significantly higher joint damage scores, and anti-CCP levels correlated with inflammatory markers and radiographic severity.¹⁹

The pattern echoes what’s seen in adults: when anti-CCP is present in JIA, it identifies children at higher risk for aggressive, polyarticular disease and worse structural outcomes. It’s not routinely ordered in all JIA subtypes, but it’s informative when a child presents with polyarticular symptoms and the clinician needs to gauge how aggressive to be with treatment.

Hepatitis C and Other Infections

Hepatitis C virus (HCV) infection is a well-known cause of false-positive rheumatoid factor, which can lead to diagnostic confusion when a patient has both HCV and joint symptoms. One of the selling points of anti-CCP has been its ability to cut through this confusion. An early study found zero elevated anti-CCP results among HCV-infected patients without cryoglobulinemia, suggesting the test reliably distinguishes HCV-related joint symptoms from true RA.²⁰

However, a later study complicated the picture somewhat by finding that a small number of HCV-infected patients without RF or cryoglobulinemia did have positive anti-CCP results.²¹ The overall message remains that anti-CCP is far more reliable than RF in the setting of HCV, but it’s not entirely immune to occasional false positives in infection.

Ulcerative Colitis

Even some gastrointestinal autoimmune conditions can produce anti-CCP antibodies. A study of ulcerative colitis patients detected anti-CCP positivity in about 11%.²² This is low compared to RA but high enough to generate unexpected lab findings, especially in a patient being screened broadly for autoimmune causes of joint pain. Joint symptoms are common in inflammatory bowel disease, and an anti-CCP result in that context requires careful clinical interpretation rather than an automatic assumption of RA.

The Smoking and Genetic Connection

One of the most compelling stories in RA research is how anti-CCP antibodies develop in the first place. Smoking is a major environmental trigger, but its effect depends heavily on genetics. People who carry certain HLA-DRB1 gene variants (known collectively as the “shared epitope”) and also smoke have a dramatically elevated risk of developing anti-CCP-positive RA. One study found that the combination of heavy smoking and the shared epitope roughly doubled what you’d expect from adding the individual risks together, indicating a true gene-environment interaction.²³

Crucially, this interaction is specific to anti-CCP-positive RA. A study comparing smokers with and without the shared epitope found that the odds of anti-CCP antibodies were about five times higher in those who had both risk factors, compared to those who had neither. Having the genetic variant alone roughly tripled the odds, while smoking alone barely moved the needle.²⁴ The working theory is that cigarette smoke promotes citrullination of proteins in the lungs, and in genetically susceptible people, the immune system learns to attack those modified proteins, eventually leading to anti-CCP antibodies and then joint disease.

The Periodontitis Link

Another mucosal surface implicated in anti-CCP development is the gums. The bacterium Porphyromonas gingivalis, a major player in gum disease, produces an enzyme that can citrullinate human proteins, potentially priming the immune response. A study of at-risk individuals who were anti-CCP positive but had no arthritis found they had higher abundance of P. gingivalis at periodontal sites than both healthy participants and people with early RA.²⁵

Among people who already have RA, studies have found correlations between P. gingivalis antibody levels and anti-CCP subtypes, with higher bacterial antibody titers linked to higher inflammatory markers.²⁶ That said, the story is not as clean as early headlines suggested. A more recent study of RA patients found no significant association between the bacterial load of P. gingivalis and anti-CCP levels, suggesting the relationship may be more complex than a straightforward cause-and-effect.²⁷ The field is still working out whether treating gum disease could meaningfully change RA outcomes.

How Anti-CCP Status Shapes Treatment Choices

Anti-CCP isn’t just a diagnostic or prognostic marker. It’s increasingly relevant to treatment selection. One of the clearest findings involves abatacept, a biologic that works by blocking immune-cell activation. A large observational study found that anti-CCP-positive patients starting abatacept had roughly twice the improvement in disease activity scores compared to anti-CCP-negative patients. That gap didn’t exist for people starting TNF-inhibitor drugs, which worked about equally well regardless of anti-CCP status.²⁸

Rituximab, another biologic that depletes B cells, also appears to work better in anti-CCP-positive patients, especially those with high titers. One study found that patients with anti-CCP levels at or above 1,000 U/mL had about five times the odds of a good treatment response compared to those with lower levels.²⁹ These findings are pushing the field toward a more personalized approach: your antibody profile may help determine which drug you start, or at least which drugs your rheumatologist reaches for first.

The flip side is that seronegative RA, where both anti-CCP and RF are negative, can be harder to treat effectively with certain biologics. This doesn’t mean treatment won’t work, but it does mean the evidence for choosing one drug over another is weaker, and clinical decision-making relies more on other disease features.³⁰

When Anti-CCP Is Positive but No Disease Is Found

A question that understandably worries people: what if you test positive for anti-CCP but feel perfectly fine? A nationwide study examining testing patterns found that about 35% of patients who had only an anti-CCP test ordered came back positive, and of those, roughly 40% received an RA diagnosis.³¹ That means a substantial fraction of anti-CCP-positive individuals do not end up with RA, at least not at the time of testing.

Some of these people will go on to develop RA years later, consistent with the pre-clinical autoimmunity window described earlier. Others may have one of the other conditions discussed above, or they may remain healthy indefinitely with circulating antibodies that never cause problems. The evidence isn’t mature enough to say exactly what proportion will eventually develop disease, but the blood donor study showing antibodies present a median of 4.5 years before symptoms gives some sense of the timeline involved.² For now, a positive anti-CCP in an otherwise healthy person typically leads to monitoring rather than treatment, with attention to any emerging joint symptoms, smoking cessation if applicable, and possibly dental health given the periodontitis link.

Improvements in Testing Over Time

The anti-CCP test itself has evolved. The original version (CCP1) has been largely replaced by the second-generation test (CCP2), which performs better both diagnostically and prognostically. A head-to-head comparison found that CCP2 had a significantly greater area under the curve on diagnostic accuracy analyses, meaning it was better at distinguishing RA patients from non-RA patients at every sensitivity threshold.³² Most labs today use CCP2 or newer iterations, so if you’re comparing results over time, it’s worth confirming which generation of the test was used.